SCHEMBL10112382

SCHEMBL10112382

COC(=O)c1ccc(-c2c3ccccc3c(-c3ccc(C(=O)OC)cc3)c3cc(N(c4ccccc4)c4ccc(N(c5ccccc5)c5ccccc5)cc4)ccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
EGFR P00533 1/20 0.45
GPR84 Q9NQS5 1/20 0.45
TNKS O95271 2/20 0.43
KIF11 P52732 1/20 0.43
PTPN1 P18031 1/20 0.43
MAPK1 P28482 1/20 0.42
ROCK2 O75116 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
MAPK8 P45983 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112619 0.89 ALDH1A1 (0.43) MEN1KMT2AEGFRGPR84MAPT
SCHEMBL10112384 0.88 GABRG2 (0.44) TSHRMEN1KMT2AKIF11RAB9A
SCHEMBL10112492 0.87 KDM4E (0.42) MEN1KMT2AGPR84MAPTMAPK8
SCHEMBL10112369 0.85 TTR (0.41) TSHREGFRTNKS
SCHEMBL8364599 0.83 TSHR (0.60) TSHRMEN1KMT2AEGFRPTPN1
SCHEMBL10112381 0.83 MEN1 (0.41) TSHRMEN1KMT2AEGFRGPR84
SCHEMBL4408743 0.82 TSHR (0.67) TSHRMEN1KMT2APTPN1ROCK2
SCHEMBL13304292 0.82 ALDH1A1 (0.42) TSHRMEN1KMT2AGPR84MAPK1
SCHEMBL29464062 0.82 TSHR (0.61) TSHRMEN1KMT2AEGFRGPR84
SCHEMBL10129332 0.81 HPGD (0.45) TSHRMEN1KMT2AMAPK1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative AMY1A, CYP1A1, CRY1 TSHR 4186/4885MEN1 711/4885KMT2A 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.